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Abstract 
Background 
Animal experiment studies have revealed a positive association between intake of citrus fruits and 
bone health. Nomilin, a limonoid present in citrus fruits, is reported to have many biological 
activities in mammalian systems, but the mechanism of nomilin on bone metabolism regulation is 
currently unclear. 
Purpose 
To reveal the mechanism of nomilin on osteoclastic differentiation of mouse primary bone 
marrow-derived macrophages (BMMs) and the mouse RAW 264.7 macrophage cell line into 
osteoclasts.  
Study design 
Controlled laboratory study. Effects of nomilin on osteoclastic differentiation were studied in in vitro 
cell cultures. 
Methods 
Cell viability of RAW 264.7 cells and BMMs was measured with the Cell Counting Kit. 
TRAP-positive multinucleated cells were counted as osteoclast cell numbers. The number and area 
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of resorption pits were measured as bone-resorbing activity. Osteoclast-specific genes expression 
was evaluated by quantitative real-time PCR; and proteins expression was evaluated by western blot. 
Results 
Nomilin significantly decreased TRAP-positive multinucleated cell numbers compared with the 
control, and exhibited no cytotoxicity. Nomilin decreased bone resorption activity. Nomilin 
downregulated osteoclast-specific genes, NFATc1 and TRAP mRNA levels. Furthermore, nomilin 
suppressed MAPK signaling pathways. 
Conclusion 
This study demonstrates clearly that nomilin has inhibitory effects on osteoclastic differentiation in 
vitro. These findings indicate that nomilin-containing herbal preparations have potential utility for 
the prevention of bone metabolic diseases. 
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Abbreviations: 
α-MEM, alpha-modified Eagle’s medium; BMMs, bone marrow-derived macrophages; ERK, 
extracellular signal-regulated kinase; FBS, fetal bovine serum; JNK, c-Jun- N-terminal kinase;  
MAPK, mitogen-activated protein kinase; M-CSF, macrophage colony stimulating factor; PCR, 
polymerase chain reaction; RANK, receptor activator of NF-κB; RANKL, receptor activator of 
NF-κB ligand; TRAP, tartrate-resistant acid phosphatase  
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Introduction 
Bone metabolic balance is maintained by osteoclast-mediated bone resorption and 
osteoblast-mediated bone formation. Bone metabolic diseases, such as osteoporosis, are caused by an 
imbalance in bone metabolism, so that osteoclastic bone resorption exceeds osteoblastic bone 
formation (Boyle et al., 2003). Osteoclasts are multinucleated cells that differentiated from cells of 
the monocyte/macrophage lineage. Macrophage colony stimulating factor (M-CSF) and receptor 
activator of NF-κB ligand (RANKL) are essential cytokines for osteoclast differentiation. Ligation of 
RANKL to the receptor activator of NF-κB (RANK) activates mitogen-activated protein kinases 
(MAPKs) pathway, including extracellular signal-regulated kinase (ERK), c-Jun- N-terminal kinase 
(JNK), and p38. These signaling pathways, together with other signaling pathways, including M-CSF, 
initiate the expression of NFATc1, a master transcription factor that regulates the differentiation of 
osteoclasts. NFATc1 regulates the expression of osteoclast-specific genes, such as tartrate-resistant 
acid phosphatase (TRAP) (Wada et al., 2006, Takayanagi et al., 2002 and Asagiri and Takayanagi 
2007).  
Epidemiology studies have revealed a positive association between increased consumption 
of fruit and vegetables and bone health (Liu 2003 and Liu 2000). Furthermore, previous rodent 
studies have shown that citrus crude extract, juice or pulp significantly improves bone density in rats 
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(Deyhim et al., 2006, Deyhim et al., 2008 and Mandadi et al., 2009). These studies suggest that the 
bone protective property of herbal preparations from citrus may be because of its bioactive 
compounds, such as flavonoids or limonoids. Limonoids are a group of triterpene derivatives found 
in the Rutaceae and Meliaceae families (Manners 2007). Recently, it has been reported that 
7-oxo-7-deacetoxygedunin, a gedunin-type limonoid, inhibits RANKL-induced osteoclastogenesis 
by suppressing activation of the NF-κB and mitogen-activated protein kinase (MAPK) pathways 
(Wisutsitthiwong et al., 2011). Therefore, citrus limonoids might play an important role in bone 
metabolism. Nomilin is one of the limonoids present in citrus fruits, such as yuzu (Citrus junos) or 
grapefruit, which is reported to have anti-proliferative effects on several types of cancer cells, an 
anti-hyperglycemic activity and anti-obesity properties (Minamisawa et al., 2014, Tian et al., 2001, 
Kim et al., 2013 and Ono et al., 2011). However, the effect of nomilin on bone metabolism is 
currently unclear. In this study, we investigated that nomilin would help to osteoclastic bone 
resorption. This study evaluated the effect of nomilin on the differentiation of mouse RAW 264.7 
macrophage cells and mouse primary bone marrow-derived macrophages (BMMs) into mature 
osteoclasts. 
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Materials and methods 
 
Reagents 
Nomilin was purchased from LKT Laboratories (St. Paul, MN, USA). The purity of 
nomilin is 98%. The chemical structure of nomilin is shown as Fig. 1A. Recombinant human M-CSF 
was purchased from Kyowa Hakko Kogyo (Leukoprol; Tokyo, Japan). Recombinant mouse M-CSF 
and recombinant mouse RANKL were purchased from R&D Systems, Inc. (Minneapolis, MA, USA). 
Fetal bovine serum (FBS) was purchased from Sigma-Aldrich (St. Louis, MN, USA). 
Alpha-modified Eagle’s medium (α-MEM) was purchased from GIBCO (Grand Island, NY, USA). 
Antibodies for western blot analysis were purchased from Cell Signaling Technology (Beverly, MA, 
USA) 
 
Cell culture 
Mouse RAW 264.7 macrophage cells were purchased from the American Type Culture 
Collection (Rockville, MD, USA). Mouse primary BMMs were obtained from the tibiae and femora 
of 7 week old ddY male mice and were cultured for 3 days in α-MEM containing 10% FBS and 
recombinant human M-CSF (1000 U/ml) in 100-mm tissue culture dishes. After 3 days incubation, 
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adherent cells were removed using trypsin and the isolated cells were used as BMMs (Okayasu et al., 
2012). All cells were cultured in α-MEM supplemented with 10% FBS and 100 U/mL penicillin. Cell 
cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2. Animal care and 
experiments were approved by the Animal Committee of Josai University. 
 
Cell viability 
RAW 264.7 cells were treated with various concentrations of nomilin (0.1–50 µM) or a 
dimethyl sulfoxide (DMSO) vehicle control, and incubated for 1 or 3 days. BMMs were treated with 
various concentrations of nomilin (0.1–50 µM) or DMSO vehicle control, in the presence of M-CSF 
(20 ng/ml), and incubated for 1 or 3 days. The effect of nomilin on cell viability of RAW 264.7 cells 
and BMMs was measured with the Cell Counting Kit (Dojindo Laboratories, Kumamoto, Japan) 
according to the manufacturer’s protocol. Plates were read using a microplate reader (Perkin Elmer, 
Inc, Waltham, MA, USA) at a wavelength of 450 nm. 
 
TRAP staining 
RAW 264.7 cells were seeded into 96-well plates at a density of 3 × 103 cells/well. Cells 
were treated with nomilin at the indicated concentrations or DMSO vehicle control, and cultured in 
α-MEM containing RANKL (10 ng/ml ) for 3 days. Meanwhile, BMMs were seeded into 96-well 
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plates at a density of 1 × 104 cells/well. Cells were treated with various concentrations of nomilin 
(0.1, 1 or 10 µM) or DMSO vehicle control, and cultured in α-MEM containing M-CSF (20 ng/ml ) 
and RANKL (10 ng/ml ) for 4 days. After culturing, cells were fixed and stained using the Acid 
Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich, St. Louis, MO, USA). Multinucleated cells 
were visualized by TRAP staining and numbers of TRAP-positive multinucleated cells (three or 
more nuclei per cell) were counted to determine osteoclast cell number. 
 
Bone resorption assay 
To determine the bone-resorbing activity of osteoclasts, we measured the number and area 
of resorption pits formed by BMMs on dentine slices. Briefly, BMMs were seeded onto dentine 
slices in 96-well plates at a density of 1 × 104 cells/well. Cells were treated with various 
concentrations of nomilin (0, 1 or 10 µM) and cultured in α-MEM containing M-CSF (20 ng/ml ) 
and RANKL (10 ng/ml) for 14 days. After culturing, the dentine slices were brushed to remove the 
cells, and were stained with acid hematoxylin for 2 min. Pit formation areas on dentine slices were 
scanned and analyzed qualitatively using Image J software (Kameda et al., 1997). 
 
Quantitative real-time RT-PCR 
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Total RNA was extracted from the cells using a NucleoSpin II Column Kit (Takara Bio 
Japan, Osaka, Japan). First-strand cDNA was converted with the PrimeScript™ Reagent Kit (Takara 
Bio Japan, Osaka, Japan). Quantitative real-time PCR was performed using the TaqMan Gene 
Expression Assay (Applied Biosystems, Carlsbad, CA, USA). TaqMan probes were as follows: 
NFATc1 (Mm00479445_m1) and TRAP (Mm00475698_m1). β-actin (Mm00607939_s1) was used as 
the internal control for normalization of target gene expression. 
 
 
Western blot analysis 
RAW 264.7 cells were incubated with or without 10µM nomilin for 1h and then stimulated 
with or without RANKL (20 ng/ml) for the indicated times. Cells were washed twice with ice-cold 
PBS and then lysed with RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, and 0.1% SDS) containing a protease inhibitor cocktail. Cell lysates were 
centrifuged at 15,000 rpm for 30 min, and the supernatants were collected as the protein samples. 
The protein concentration of each sample was measured with BCA Protein Assay Reagent (Thermo 
Pierce, Rockford, IL, USA). Proteins (5 µg) were separated by 10% SDS-PAGE and transferred to 
PVDF membranes. The membranes were blocked with 2% BSA in TBS-T (10 mM Tris-HCl, pH 7.4 
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containing 1.37 M NaCl and 0.1% Tween 20) for 30 min at room temperature. The membranes were 
probed with antibodies against phosphor-ERK, ERK, phospho-p38, p38, phospho-JNK, JNK and 
β-actin for 1 h at room temperature or overnight at 4°C. Horseradish peroxidase-conjugated rabbit 
anti-mouse IgG was applied as the secondary antibodies for 1 h at room temperature. Finally, labeled 
proteins were detected with EZ west Lumi plus (ATTO, Tokyo, Japan). Protein bands were analyzed 
using EZ capture MG (ATTO, Tokyo, Japan).  
 
Statistical analysis 
Results are presented as means ± standard deviation (SD). One-way analysis of variance 
(ANOVA) with Tukey’s post hoc test was used for statistical analysis. Values of p < 0.05 were 
considered significant. 
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Results 
 
Effect of nomilin on osteoclastic differentiation of RAW 264.7 cells and BMMs  
To examine the effect of nomilin on osteoclastic differentiation, RAW 264.7 cells and 
BMMs were treated with various concentrations of nomilin in the presence of RANKL. Osteoclastic 
differentiation was determined by counting TRAP-positive multinucleated cell numbers. TRAP 
staining analysis is the most popular method to confirm osteoclastic differentiation. Furthermore, we 
examined the effect of nomilin on the viability of RAW 264.7 cells and BMMs.  
Treatment with a nomilin concentration greater than 1 µM markedly decreased the 
formation of TRAP-positive multinucleated osteoclasts from RAW 264.7 cells (IC50 = 12 µM) (Fig. 
1B, C). Nomilin had no cytotoxic effect on RAW 264.7 cells at concentrations of less than 50 µM 
compared with the control treatment (Fig. 1D). Furthermore, treatment with nomilin inhibited the 
formation of TRAP-positive multi nucleated osteoclasts from BMMs, which were subjected to 
RANKL-induced osteoclastogenesis, in a dose-dependent manner (IC50 = 0.6 µM) (Fig. 2A, B). 
Nomilin had no cytotoxic effects on BMMs at concentrations of less than 50 µM compared with the 
control treatment (Fig. 2C). 
 
Effect of nomilin on osteoclastic bone resorption 
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We evaluated whether nomilin treatment could inhibit the bone resorbing activity of 
osteoclasts derived from BMMs. To examine the effect of nomilin on osteoclastic bone resorption, 
BMMs were cultured with various concentrations of nomilin in the presence of M-CSF and RANKL 
for 14 days. Pit formation areas were narrower after nomilin treatment. In addition, treatment with 
nomilin at a concentration of higher than 1 µM decreased the resorption activity and pit formation 
area of osteoclasts (Fig. 3A,B). 
 
Effect of nomilin on the gene expression of NFATc1 and TRAP  
To examine the effect of nomilin on osteoclastic gene expression in BMMs, the BMMs 
were treated with various concentrations of nomilin (1 or 10 µM) in the presence of M-CSF and 
RANKL. Osteoclastic gene expression in BMMs was determined by quantitative real-time RT-PCR. 
The expression of osteoclastic genes was induced during osteoclastogenesis, including NFATc1 and 
TRAP. Treatment with nomilin (10 µM) significantly suppressed the induction of NFATc1 mRNA 
(Fig. 3C). In addition, TRAP mRNA levels were decreased by nomilin in a dose-dependent manner 
(Fig. 3D). These results indicated that nomilin could inhibit the osteoclastic differentiation by 
suppression osteoclastic gene expression. 
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Effect of nomilin on MAPK signaling pathways 
We examined the effect of nomilin on RANKL-induced signaling pathways. We evaluated 
whether nomilin treatment affected the RANKL-induced phosphorylation of ERK, p38 and JNK. 
These signaling pathways are essential for the differentiation of osteoclasts. Treatment with nomilin 
inhibited the phosphorylation of ERK p38 and JNK (Fig. 4). These results indicated that nomilin 
could inhibit the RANKL-induced phosphorylation of MAPKs (ERK, p38 and JNK) in osteoclasts. 
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Discussion 
Bioactive citrus compounds have been shown to enhance bone mineral density in rats 
(Deyhim et al., 2006, Deyhim et al., 2008; Mandadi et al., 2009). Moreover, limonoid, which is 
present in citrus seeds, is also reported to exhibit an anti-osteoclastogenic activity in vitro 
(Wisutsitthiwong et al., 2011). In this study, we investigated the effect of nomilin, a citrus limonoid, 
on osteoclastic differentiation from both mouse RAW 264.7 cells and BMMs. 
A previous report has shown that a gedunin-type limonoid has a strong 
anti-osteoclastogenic activity in RANKL-treated RAW 264.7 cells as a model of osteoclastogenesis 
(Wisutsitthiwong et al., 2011). We used the same cell line and found that nomilin inhibited 
osteoclastic differentiation from RAW 264.7 cells without cytotoxicity. This result suggests that the 
citrus limonoid nomilin has an anti-osteoclastogenic activity.   
In vivo, osteoclasts differentiate from BMM precursors. Hence, we investigated the effect 
of nomilin on osteoclastic differentiation from primary BMMs. We demonstrated that nomilin 
reduced RANKL-induced osteoclastogenesis in a dose-dependent manner from primary BMMs. 
Bone resorption occurs in the bone matrix and is mediated by mature osteoclasts (Boyle et al., 2003). 
Nomilin suppressed osteoclastic differentiation from both RAW 264.7 cells and BMMs. In addition, 
we evaluated whether nomilin treatment could inhibit the bone-resorbing activity of osteoclasts 
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derived from BMMs. Treatment with nomilin decreased bone-resorbed areas on dentine slices 
compared with the control. Thus, nomilin has an anti-bone resorption activity. This result indicates 
that nomilin can suppress physiological bone resorption. 
In addition, we examined the effect of nomilin on the regulation of osteoclastic genes. 
NFATc1 acts as a master regulator of osteoclastogenesis and regulates the expression of TRAP, 
which is marker gene in the early stage of osteoclastic differentiation (Asagiri and Takayanagi 2007,  
Takayanagi et al., 2002). We found that treatment of nomilin suppressed NFATc1 and TRAP mRNA 
levels in osteoclasts compared with the control. These results indicate that nomilin can suppress 
osteoclastogenesis at an early stage.  
Previous reports have shown that treatment with a gedunin-type limonoid decreases the 
expression of NFATc1 by suppressing activation of the NF-κB and MAPK pathways in RAW 264.7 
cells (Wisutsitthiwong et al., 2011). It has also been reported that nomilin reduces tumor necrosis 
factor-alpha-induced p38 MAPK activity in human aortic smooth muscle cells (Kim et al., 2011). It 
has reported that RANKL-activated MAPKs (ERK, p38 and JNK) signaling has been associated with 
osteoclastogenesis (Boyle et al., 2003). The RANKL-mediated phosphorylation of these MAPKs 
upregulate NFATc1 activity (Monje et al., 2005, Matsumoto et al., 2000 and Ikeda et al 2004).  In 
this study, we evaluated the effects of nomilin on MAPK signaling pathways. Nomilin inhibited the 
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phosphorylation of ERK, p38 and JNK signaling. These results indicated that nomilin suppress 
osteoclastogenesis via suppression of RANKL-mediated phosphorylation of MAPKs (ERK, p38 and 
JNK).  
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Conclusion 
This study demonstrates for the first time that nomilin has an anti-osteoclastogenic activity 
by suppressing the expression of NFATc1 gene and the RANKL-mediated phosphorylation of 
MAPKs (ERK, p38 and JNK). These findings indicate that nomilin-containing herbal preparations 
have potential utility for the prevention of bone metabolic diseases. 
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Figure legends 
Fig. 1. Effect of nomilin on osteoclastic differentiation of RANKL-stimulated RAW 264.7 cells. (A) 
Structure of nomilin. (B) RAW 264.7 cells were treated with nomilin at the indicated concentrations 
or DMSO vehicle control, with culture in α-MEM containing RANKL (10 ng/ml) for 3 days. 
Multinucleated cells were visualized by TRAP staining. Scale bars represent 200 µm. (C) 
TRAP-positive multinucleated cells were counted to determine osteoclast numbers. (D) RAW 
264.7cells were treated with nomilin at the indicated concentrations for 1 or 3 days. Cell viability 
was measured with the Cell Counting Kit. Data are presented as means ± SD (n = 3), *p < 0.05. 
 
Fig. 2. Effect of nomilin on osteoclastic differentiation of RANKL-stimulated BMMs. (A) BMMs 
were treated with various concentrations of nomilin (0.1, 1 or 10 µM) or DMSO vehicle control, with 
culture in α-MEM containing M-CSF (20 ng/ml) and RANKL (10 ng/ml) for 4 days. Multinucleated 
cells were visualized by TRAP staining. Scale bars represent 200 µm. (B) TRAP-positive 
multinucleated cells were counted to determine osteoclast cell numbers. (C) BMMs were treated with 
nomilin at the indicated concentrations in the presence of M-CSF (20 ng/ml) and incubated for 1 or 3 
days. Cell viability was measured with the Cell Counting Kit. Data are presented as means ± SD (n = 
3), *p < 0.05. 
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Fig. 3. Effect of nomilin on osteoclastic bone resorption and mRNA expression levels of NFATc1 and 
TRAP in BMMs as analyzed by RT-PCR. BMMs were treated with various concentrations of nomilin 
(0.1, 1 or 10 µM) or DMSO vehicle control, with culture in α-MEM containing M-CSF (20 ng/ml) 
and RANKL (10 ng/ml) for 14 days. (A) Photograph of pit formation areas on dentine slices. Scale 
bars represent 20 µm. (B) Pit formation areas on a dentine slice were analyzed qualitatively using 
Image J software. Cells were treated with various concentrations of nomilin (1 or 10 µM) or DMSO 
vehicle control, with culture in α-MEM containing M-CSF (20 ng/ml ) and RANKL (20 ng/ml) for 6 
h. RT-PCR analysis of the expression levels of NFATc1 (C) and TRAP (D) mRNA are shown. Results 
are expressed as relative values to β-actin. Data are presented as means ± SD (n = 3), *p < 0.05. 
 
Fig. 4. Effect of nomilin on MAPK pathways. RAW 264.7 cells were incubated with or without 10 
µM nomilin for 1h and then stimulated with or without RANKL (20 ng/ml) for the indicated time. 
The cell lysates were analyzed by Western blotting. The data are representative of 3 independent 
experiments.
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